Clinical Trial Update: Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy [Phase 1, Phase 2]

View source ↗

Summary

An early-phase clinical trial is evaluating Radium-223 dichloride alone or in combination with M3814 and/or Avelumab for metastatic castration-resistant prostat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Avelumab (avelumab)
• M3814
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 1, Phase 2 | Status: RECRUITING